Current Trials

ATLAS ACS 2 TIMI 51 (The second trial of Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome)

A randomised, double-blind, placebo-controlled, event-driven multicenter study to evaluate the efficacy and safety of Rivaroxaban in subjects with a recent acute coronary syndrome.

This is a randomised, double-blind, placebo-controlled, event driven multicenter study to evaluate the efficacy and safety of Rivaroxaban in subjects with a recent acute coronary syndrome. The purpose is to determine whether Rivaroxaban in addition to standard care reduces the risk of the composite cardiovascular (CV) death, myocardial infarction (MI) or stroke in participants with a recent ACS compared with placebo in addition to standard care.

Cangrelor versus standard theraphy to achieve optimal management of platelet inhibition

A clinical trial comparing cangrelor to clopidogrel standard of care therapy in subjects who require percutaneous coronary intervention.

IMPROVE IT – IMProved Reduction of Outcomes: Vytorin Efficacy International Trial.

A Multicentre, Double-Blind, Randomised Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome.

The main aim of the trial is to evaluate the benefit of Vytorin (study medication) compared to Simvastatin (control therapy) in participants who have experienced a heart attack or chest pain which required treatment in a hospital. This is a phase IIIb trial meaning that both of the medications that will be used in the trial have been approved by the government for use by doctors in New Zealand.

Inhibition of δ-PROTEin kinase C for the reducTION of infarct size in Acute Myocardial Infarction

Phase IIb clinical trial investigating whether the new drug KAI-9803 can reduce damage to the heart muscle, in people who have a serious heart attack, known as an ST elevation myocardial infarction (STEMI).

Study Comparing Rivaroxaban (study drug) with Warfarin in patients being treated for non-Valvular Atrial Fibrillation.

A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) with Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects with Non-Valvular Atrial Fibrillation.

The main aim of this study is to demonstrate that rivaroxaban (study drug), a direct factor Xa inhibitor, is as good as the standard treatment warfarin for the prevention of thromboembolic events in subjects with non-valvular atrial fibrillation.

STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY

A Multi-centre, Randomised, Double-Blind, Placebo-controlled, Event-driven Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE).

This is a phase III randomized, multi-centre, placebo-controlled, double-blind, parallel group, event-driven study involving an investigational drug darapladib (SB-480848). This study will compare the chronic effects of darapladib versus placebo when added to the standard of care, on the incidence of major adverse cardiovascular events (MACE) in high risk patients with chronic Coronary Heart Disease (CHD).

Surgical Treatment for Ischemic Heart Failure (STICH) Trial is a multicentre, international, randomised trial comparing medical treatment + CABG, and medical treatment + CABG + surgical ventricular restoration (SVR) in 2,425 patients. Follow -up will be between 2 to 6 years.

STICHES (Surgical Treatment for Ischemic Heart Failure Extended Study.

TECOS: Trial Evaluating Cardiovascular Outcomes with Sitagliptin

A randomised, placebo controlled clinical Trial to Evaluate Cardiovascular Outcomes after treatment with Sitagliptin in patients with Type 2 Diabetes Mellitus and inadequate glycemic control on mono-or dual combination oral antihyperlycemic therapy (TECOS)

This is a multinational, placebo-controlled, double-blind, randomised, parallel-group pragmatic clinical trial. The purpose of this study is to assess the impact of sitagliptin therapy upon cardiovascular (CV) outcomes in a large population from a diverse group of countries and practice environments.

A Multi-centre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRAâ?¢CER)

This is a phase III randomised, multicentre, double-blind, placebo-controlled, balanced-parallel-groups study involving the use of an investigational drug SCH 530348. This study will evaluate the safety and efficacy of SCH 530348 in addition to the standard of care in participants with atherosclerotic disease/acute coronary syndrome (ACS) and determine if there is a clinical benefit relative to standard of care alone.